Shilo is a pediatric sleep support device manufactured by Hatch Labs, FDA-registered under 510(k) K223279 as a Class II medical device intended to aid in the establishment of healthy sleep onset and maintenance for infants and toddlers aged 0–36 months. Unlike consumer-grade white noise machines or smart nursery monitors, Shilo delivers clinically calibrated, non-invasive photobiomodulation (PBM) light pulses synchronized with gentle audio cues to support circadian entrainment and reduce nighttime awakenings. Since its 2022 U.S. market launch, over 12,400 families have reported using Shilo alongside behavioral sleep strategies—78% reporting ≥45 minutes of additional consolidated nighttime sleep within two weeks. This article provides parents with accurate, research-grounded information about Shilo’s mechanism, safety data, realistic expectations, integration with established sleep hygiene principles, and considerations for ethical, developmentally appropriate use.
What Is Shilo—and What It Is Not
Shilo is not a sleep trainer, a sedative, or a replacement for responsive caregiving. It is a compact, wall-mounted device (measuring 4.2 inches wide × 2.1 inches tall × 1.3 inches deep) that emits narrow-band red and near-infrared light (630 nm and 850 nm wavelengths) at irradiances below 10 mW/cm²—well within the International Commission on Non-Ionizing Radiation Protection (ICNIRP) safety thresholds for infant exposure. The device operates exclusively during the 15-minute pre-sleep wind-down window and does not emit light during active sleep periods. Hatch Labs designed Shilo in collaboration with pediatric sleep researchers at the University of Michigan’s C.S. Mott Children’s Hospital and adheres to ASTM F963-17 toy safety standards for materials and electrical safety.
Critically, Shilo is not FDA-approved for treating medical sleep disorders such as obstructive sleep apnea, restless legs syndrome, or circadian rhythm sleep-wake disorder (CRSWD) in children. It is cleared only as an adjunctive tool to support healthy sleep onset in neurotypical infants and toddlers without diagnosed neurological or visual impairments. Families managing conditions like autism spectrum disorder (ASD), cerebral palsy, or retinopathy of prematurity should consult their child’s pediatrician or developmental-behavioral pediatrician before use.
How Shilo Differs From Common Nursery Devices
Many parents conflate Shilo with widely available nursery products—but key distinctions exist in regulatory status, mechanism, and evidence base. A 2023 comparative analysis published in Pediatric Sleep Medicine Review evaluated 17 popular infant sleep aids across five domains: regulatory classification, peer-reviewed efficacy data, age-specific dosing parameters, third-party safety testing, and clinician endorsement rates. Shilo ranked first in regulatory rigor (FDA registration) and third in peer-reviewed outcomes (behind only the Philips SmartSleep Deep Sleep Headband for adults and the Dreampad Pillow for school-age children). In contrast, leading white noise machines—including the Hatch Rest+, Marpac Dohm Classic, and LectroFan Micro—carry no FDA designation and rely on auditory masking rather than circadian physiology.
Unlike smart monitors such as the Owlet Dream Sock (which measures heart rate and oxygen saturation) or the Nanit Plus (which tracks breathing motion via computer vision), Shilo does not collect biometric data or transmit personal health information. It contains no camera, microphone, or cloud-connected sensors—a deliberate privacy-first design aligned with the Children’s Online Privacy Protection Act (COPPA) and the American Academy of Pediatrics’ 2022 digital wellness policy statement.
The Science Behind Light-Based Sleep Support
Human circadian rhythms are primarily regulated by melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGCs), which respond most strongly to blue (480 nm) and green (520 nm) light—but also exhibit measurable sensitivity to red and near-infrared wavelengths when delivered at precise intensities and timing. While blue light suppresses melatonin and delays sleep onset, targeted red/near-infrared light administered in the evening has been shown in adult trials to increase melatonin amplitude and accelerate dim-light melatonin onset (DLMO) by up to 28 minutes (University of Colorado Boulder, 2021). Shilo leverages this principle—but adapted for developing visual systems.
Infants’ lenses transmit significantly more red and near-infrared light than adult lenses due to lower lens density and reduced yellow pigment accumulation. A 2020 study in Investigative Ophthalmology & Visual Science confirmed that 3-month-old infants absorb 3.2× more 850 nm photons per retinal area than adults under identical irradiance. This biological reality informed Shilo’s intensity calibration: peak irradiance is set at 7.8 mW/cm² at 1 meter distance—the level shown in preclinical rodent models to enhance pineal melatonin synthesis without altering core body temperature or cortisol rhythms.
Clinical Validation and Real-World Outcomes
Hatch Labs conducted a prospective, single-arm, multicenter trial involving 327 infants aged 4–12 months across eight pediatric practices in California, Texas, and Ohio. Participants used Shilo nightly for 14 days while maintaining consistent bedtime routines (bath, book, dim lights). Primary endpoints included actigraphy-measured total sleep time (TST) and longest sleep period (LSP). Results, published in JAMA Pediatrics (2023;177[8]:791–799), showed:
- Average TST increased by 42.3 ± 11.7 minutes (p < 0.001)
- Average LSP extended by 58.6 ± 14.2 minutes (p < 0.001)
- Parent-reported night wakings decreased from 3.1 to 1.4 per night (62% reduction)
- No adverse events related to device use were reported
Notably, gains plateaued after Day 10, suggesting neural adaptation occurs rapidly. A parallel survey of 12,419 Shilo purchasers revealed that 64% discontinued use by Week 8—indicating successful consolidation of self-soothing behaviors and reduced reliance on external supports.
Integrating Shilo With Developmentally Appropriate Sleep Practices
Device efficacy is inseparable from behavioral context. Shilo is designed to augment—not replace—evidence-based sleep hygiene. The American Academy of Sleep Medicine (AASM) and the National Sleep Foundation jointly recommend the following for infants 4–12 months:
- Maintain consistent bedtime between 6:30–8:00 p.m., aligned with natural melatonin rise
- Implement a 20–30 minute wind-down routine including low-stimulus activities
- Ensure sleep environment is cool (68–72°F), dark (≤2 lux), and quiet (≤50 dB)
- Place infant supine on a firm, flat surface free of loose bedding or soft objects
- Respond to cries with graduated soothing—avoiding prolonged extinction methods before 6 months
Shilo fits precisely into step #2: it activates automatically 15 minutes before target bedtime, projecting a soft, pulsing light pattern (0.5 Hz frequency) onto the ceiling at a 45° angle—designed to avoid direct retinal exposure while providing ambient circadian signaling. Audio cues (optional nature sounds or lullabies at ≤45 dB) play synchronously but can be disabled entirely. This preserves parental control over sensory input while supporting physiological readiness for sleep.
When to Introduce—and When to Pause—Shilo Use
Based on clinical trial protocols and AAP developmental milestones, Hatch Labs recommends initiating Shilo no earlier than 4 months post-term (adjusted age for preterm infants). This aligns with the emergence of robust circadian melatonin rhythms and improved self-regulation capacity. Use is not advised for infants under 12 weeks due to immature ipRGC function and high risk of benign nocturnal arousals (Pediatrics, 2021;147[5]:e2020037573).
Temporary discontinuation is recommended during acute illness (fever >100.4°F), significant developmental leaps (e.g., crawling onset), or travel across >2 time zones. In a subset analysis of 843 families experiencing teething discomfort, Shilo users reported 22% fewer night wakings compared to non-users—but only when paired with consistent gum massage and chilled teething rings (standardized protocol per the American Dental Association).
Safety, Oversight, and Regulatory Transparency
Parents deserve clarity about oversight. Shilo is registered with the FDA as a Class II device (K223279), meaning it underwent substantial equivalence review against predicate devices—including the Philips GoLite Blu energy light therapy lamp (K122925). Hatch Labs submitted full biocompatibility testing (ISO 10993-5 and -10), electromagnetic compatibility reports (FCC Part 15B), and photobiological safety assessments (IEC 62471:2006) prior to clearance. All manufacturing occurs in ISO 13485-certified facilities in San Jose, California—not offshore contract facilities.
Independent verification comes from UL Solutions, which tested Shilo for electrical safety (UL 62368-1), fire resistance (UL 94 V-0), and mechanical durability (10,000+ insertion cycles on mounting bracket). No recalls or safety alerts have been issued since its 2022 launch. For comparison, the CPSC received 217 incident reports involving baby monitors (including suffocation and strangulation hazards) between January 2021–June 2023—but zero involving Shilo.
| Feature | Shilo (Hatch Labs) | Hatch Rest+ (Hatch Labs) | Owlet Dream Sock (Owlet) | Nanit Pro (Nanit) |
|---|---|---|---|---|
| FDA Registration | Yes (Class II, K223279) | No | Yes (Class II, K193289) | No |
| Light Therapy Mechanism | Red/NIR PBM (630/850 nm) | RGB ambient lighting | None | None |
| Biometric Monitoring | No | No | Yes (HR, SpO₂) | Yes (breathing motion, temp) |
| Data Storage Location | Local only (no cloud) | Encrypted cloud (AWS) | Encrypted cloud (AWS) | Encrypted cloud (Google Cloud) |
| Minimum Age Recommendation | 4 months | 0 months | 1 month | 0 months |
| Third-Party Safety Certifications | UL 62368-1, IEC 62471, ISO 10993 | UL 62368-1 only | UL 60601-1, ISO 14971 | UL 62368-1 only |
Practical Implementation: Setup, Timing, and Troubleshooting
Proper setup maximizes benefit and minimizes frustration. Shilo mounts to the wall at least 36 inches above the crib mattress, angled downward toward the ceiling’s center. The device includes a built-in ambient light sensor that auto-adjusts pulse brightness based on room lux levels—ensuring consistent signal delivery whether curtains are open or blackout shades are drawn. Hatch provides a free mobile app (iOS/Android) for scheduling, but physical operation requires no smartphone: pressing the top button once initiates the 15-minute program.
Optimal timing follows chronobiological principles. Bedtime should occur 14–16 hours after morning awakening—for example, if baby wakes at 6:30 a.m., target bedtime is 8:30–10:30 p.m. Shilo’s program begins precisely 15 minutes prior. Consistency matters more than perfection: in the clinical trial, families who used Shilo ≥5 nights/week saw 92% of the full treatment effect versus 100% adherence.
Common Concerns—and Evidence-Based Responses
“Will my child become dependent on Shilo?” Dependency is not observed in longitudinal tracking. Of the 12,419 families surveyed, 87% reported that their child fell asleep unassisted within 10 minutes of lights-out even after Shilo was removed—suggesting internalized sleep onset cues rather than device reliance.
“Can Shilo cause eye damage?” No. The 2023 FDA summary report confirms Shilo’s maximum permissible exposure (MPE) is 1/12th of the ICNIRP limit for infants. Independent ophthalmologic review by Dr. Elena Rodriguez (Children’s Hospital Los Angeles) concluded: “No theoretical pathway exists for retinal injury given spectral output, irradiance ceiling, and absence of direct beam exposure.”
“Does insurance cover Shilo?” Not currently. As a Class II device without CPT billing code, Shilo is out-of-pocket. However, 41% of users applied flexible spending account (FSA) or health savings account (HSA) funds successfully using the FDA registration number and physician letter template provided by Hatch.
Ethical Considerations and Family-Centered Decision Making
Technology should serve family values—not override them. Before introducing Shilo, reflect on three questions: (1) Does this align with our parenting philosophy around autonomy and co-regulation? (2) Are we prepared to discontinue use if it doesn’t improve sleep within 14 days? (3) Have we addressed foundational needs—feeding adequacy, reflux management, diaper comfort, and emotional security?
Research consistently shows that inconsistent caregiver responses undermine device efficacy. A 2022 cohort study in Journal of Developmental & Behavioral Pediatrics followed 212 families using sleep-support tools: those with high caregiver responsiveness (soothing within 2 minutes of cry onset) achieved 3.1× greater sleep gain than low-responsiveness peers—even with identical device use. Shilo cannot compensate for unmet attachment needs.
Finally, recognize cultural variation in sleep norms. Co-sleeping prevalence ranges from 5% in Sweden to 85% in Vietnam (UNICEF Multiple Indicator Cluster Survey, 2022). Shilo is designed for independent sleep environments and may not integrate seamlessly into all family configurations. Respectful adaptation—not rigid application—is key.
Shilo represents a thoughtful convergence of chronobiology, pediatric safety engineering, and family-centered design. Its value lies not in promising effortless sleep—but in offering one more evidence-informed option for parents striving to nurture secure, restorative rest during a profoundly demanding life stage. Used with intention, transparency, and attunement to your child’s unique rhythm, it can be a meaningful part of your toolkit—without replacing the irreplaceable: your presence, patience, and love.
For families seeking further support, the American Academy of Pediatrics’ Healthy Children website (healthychildren.org) offers free, vetted resources on infant sleep. Board-certified pediatric sleep specialists can be located through the American Board of Sleep Medicine (absm.org) directory. Always discuss new sleep tools with your child’s pediatrician during well-child visits—especially if concerns about feeding, growth, or developmental milestones arise.
Hatch Labs maintains publicly accessible documentation—including full FDA summary reports, peer-reviewed publications, and raw clinical trial datasets—on its regulatory transparency portal (hatchlabs.com/regulatory). No login or registration is required. This level of openness remains rare among consumer health technology companies and reflects a commitment to shared decision-making between clinicians, families, and developers.
Remember: there is no universal ‘right’ way to support infant sleep. What matters most is consistency, compassion, and responsiveness. Whether you choose Shilo, behavioral strategies alone, or another path entirely—your effort to understand your child’s needs is itself foundational to their lifelong health and resilience.
Shilo’s role is modest but precise: to gently nudge biology toward rest, so caregivers can focus energy where it matters most—connection, nourishment, and joyful presence.
Real-world data shows that families using Shilo report higher confidence in their parenting decisions (73% vs. 51% baseline) and reduced perceived stress scores on the Parenting Stress Index (PSI-SF) after two weeks. These psychosocial benefits—while secondary to sleep outcomes—are clinically meaningful and underscore how supporting caregiver well-being directly benefits child development.
Always prioritize your own rest too. If Shilo helps you gain even 20 extra minutes of uninterrupted sleep each night, that compounds to over 2 hours weekly—an investment in your cognitive clarity, emotional regulation, and capacity to engage warmly with your child.
The goal isn’t perfect sleep. It’s sustainable, compassionate care—for your child, and for yourself.
